Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|April 18, 2020
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled StudyKathleen Weisel, Scott Berger, Kim Papp, et al.
British Journal of Clinical Pharmacology|August 11, 2021
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)Kimberley Jackson, Laiyi Chua, Nieves Velez de Mendizabal, et al.
Annals of the Rheumatic Diseases|December 16, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 2, 2025
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic DermatitisGilles Tiraboschi, Kim Papp, Thomas Bieber, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2020
Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA TrialGordon Sussman, Jacques Hébert, Wayne Gulliver, et al.
The British Journal of Dermatology|January 18, 2022
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trialsGil Yosipovitch, Kim Papp, Seth Forman, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|April 18, 2020
Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled StudyKathleen Weisel, Scott Berger, Kim Papp, et al.
British Journal of Clinical Pharmacology|August 11, 2021
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)Kimberley Jackson, Laiyi Chua, Nieves Velez de Mendizabal, et al.
Annals of the Rheumatic Diseases|December 16, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 2, 2025
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic DermatitisGilles Tiraboschi, Kim Papp, Thomas Bieber, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2020
Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA TrialGordon Sussman, Jacques Hébert, Wayne Gulliver, et al.
The British Journal of Dermatology|January 18, 2022
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trialsGil Yosipovitch, Kim Papp, Seth Forman, et al.
Pageof 14